Abstract
The dose-related adverse effects of MDM2‒P53 inhibitors have caused significant concern in the development of clinical safe anticancer agents. Herein we report an unprecedented homo-PROTAC strategy for more effective disruption of MDM2‒P53 interaction. The design concept is inspired by the capacity of sub-stoichiometric catalytic PROTACs enabling to degrade an unwanted protein and the dual functions of MDM2 as an E3 ubiquitin ligase and a binding protein with tumor suppressor P53. The new homo-PROTACs are designed to induce self-degradation of MDM2. The results of the investigation have shown that PROTAC 11a efficiently dimerizes MDM2 with highly competitive binding activity and induces proteasome-dependent self-degradation of MDM2 in A549 non-small cell lung cancer cells. Furthermore, markedly, enantiomer 11a-1 exhibits potent in vivo antitumor activity in A549 xenograft nude mouse model, which is the first example of homo-PROTAC with in vivo therapeutic potency. This study demonstrates the potential of the homo-PROTAC as an alternative chemical tool for tumorigenic MDM2 knockdown, which could be developed into a safe therapy for cancer treatment.
Original language | English (US) |
---|---|
Pages (from-to) | 1617-1628 |
Number of pages | 12 |
Journal | Acta Pharmaceutica Sinica B |
Volume | 11 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2021 |
Keywords
- Homo-PROTAC
- In vivo antitumor activity
- MDM2
- Self-degradation
ASJC Scopus subject areas
- Pharmacology, Toxicology and Pharmaceutics(all)